AMP 2025

SOPHiA GENETICS is excited to attend this year’s Association of Molecular Pathology (AMP) Annual Meeting!

Find us at booth #921 to learn about how we are enabling breakthrough innovations in cancer research.

Including our latest launch: the new SOPHiA DDM™ Community Myeloid Solution — built to magnify myeloid discovery. A comprehensive, DNA-only solution that enables researchers to dig deeper into the molecular landscape of myeloid cancers.
As well as our continued collaboration with Memorial Sloan Kettering cancer Center to decentralize MSK-ACCESS and MSK-IMPACT we are committed to supporting clinical researchers with variant detection and analysis, biomarker discovery, and therapy selection.

Full Program

Wednesday, November 12, 10:00 – 10:50 am | Corporate Workshops | 160C Level 1
Elevating CGP with Agile Solutions: The New MSK-IMPACT® Flex powered with SOPHiA DDM™

Speakers:

Lina Li, Director, Product Management, Application, SOPHiA GENETICS
Izabela Matyszczak, Technical Product Management Expert, SOPHiA GENETICS
Dr. Rehan Mujeeb Faridi, PhD, HCLD/CC (ABB), Director of Molecular Diagnostics at OncoHelix

Add to calendar

Wednesday, November 12, 11:00 – 11:50 am | Corporate Workshops | 160C Level 1
Redefining Precision Oncology with MSK-ACCESS® powered with SOPHiA DDM™

Speakers:

Florian Klemm, Technical Product Management Expert, SOPHiA GENETICS
Maria Fernanda Milanezi, Head of Molecular Pathology at Dasa Genomica Laboratory, Dasa Brazil
Ryan Demers, Global Diagnostics Director, Liquid Biopsy & Early Diagnostics Strategy, AstraZeneca

Add to calendar

Posters Presentations

Friday, November 14, 9:15am – 10:15am | Poster number: ST044
Robust RNA profiling using the SOPHiA DDM™ RNAtarget Oncology Solution with FFPE tumor samples

Presented by Izabela Matyszczak, Technical Product Management Expert, SOPHiA GENETICS

Authored by: Izabela Matyszczak, Slawomir Kubik, Jonathan Bieler, Ewan Smith, Jonathan Lopez, Alexandre Harlé, Christian Pozzorini, Zhenyu Xu

Add to calendar

Saturday, November 15, 9:15am – 10:15am | Poster number: ST041
MSK-IMPACT Flex powered with SOPHiA DDM™ enables sample-specific comprehensive genomic profiling through selective analysis of DNA and RNA biomarkers

Presented by Izabela Matyszczak, Technical Product Management Expert, SOPHiA GENETICS

Authored by: Izabela Matyszczak, Christian Pozzorini, Gregoire André, Tommaso Coletta, Amjad Alkodsi, Frederic Michaud, Yvan Wenger, Elia Magrinelli, Anjali Anjali, Zhenyu Xu

Add to calendar

Book a Meeting

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Institution(Required)

Job Function(Required)

Area of Interest(Required)

Email(Required)

Phone(Required)

Country(Required)

Select US State

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

This field is hidden when viewing the form

Job Title/Industry(Required)

CAPTCHA

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expresseda during this presentation are these of the speaker and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services